Provectus Biopharmaceuticals (OTC: PVCT)
Provectus Biopharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Provectus Biopharmaceuticals Company Info
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.
News & Analysis
Shorts Are Piling Into These Stocks. Should You Be Worried?
Do short-sellers have these three stocks pegged? You be the judge!
3 Stocks Crushed by the Market Last Week
Down by double digits in just a few days. Why these 3 health-care stocks were the most horrendous performers this week.
63% Implosion: The Epic Collapse of Provectus Biopharmaceuticals, Inc
Provectus' roller coaster ride has left investors nauseous.
5 of Last Week's Biggest Losers
These five stocks suffered double-digit percentage declines last week.
This Week in Biotech: PTC Therapeutics Surprises, Isis' Data Dazzles, and Provectus Sinks
Four positive clinical updates, a billion-dollar licensing deal, a surprising positive opinion for one company in the EU, and a rough NYSEArca debut for one biopharma are this week's top biotech stories.
Why Provectus Biopharmaceuticals Inc. Shares Plummeted
Provectus shares tumble after it refutes misleading claims in a blog. Find out what investors should really be paying attention to instead.
3 Humongous Health-Care Stocks This Week
Which health-care stocks stood out as the most humongous winners this week? Provectus, Inovio, and United Therapeutics take the honors.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.